Staffing & Employment Services
Compare Stocks
5 / 10Stock Comparison
VOLT vs KELYA vs TBI vs CCRN vs MAN
Revenue, margins, valuation, and 5-year total return — side by side.
Staffing & Employment Services
Staffing & Employment Services
Medical - Care Facilities
Staffing & Employment Services
VOLT vs KELYA vs TBI vs CCRN vs MAN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Staffing & Employment Services | Staffing & Employment Services | Staffing & Employment Services | Medical - Care Facilities | Staffing & Employment Services |
| Market Cap | $891M | $349M | $182M | $423M | $1.41B |
| Revenue (TTM) | $895M | $3.09B | $1.25B | $761M | $17.96B |
| Net Income (TTM) | $-460K | $-266M | $-53M | $-99M | $-13M |
| Gross Margin | 15.9% | 26.3% | 28.4% | 18.2% | 16.7% |
| Operating Margin | 0.2% | -2.8% | -2.6% | -0.9% | 0.8% |
| Forward P/E | 663.2x | 11.0x | — | 133.8x | 8.3x |
| Total Debt | $100M | $159M | $171M | $2M | $2.39B |
| Cash & Equiv. | $71M | $33M | $25M | $109M | $871M |
VOLT vs KELYA vs TBI vs CCRN vs MAN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Volt Information Sc… (VOLT) | 100 | 4634.0 | +4534.0% |
| Kelly Services, Inc. (KELYA) | 100 | 64.7 | -35.3% |
| TrueBlue, Inc. (TBI) | 100 | 38.9 | -61.1% |
| Cross Country Healt… (CCRN) | 100 | 215.7 | +115.7% |
| ManpowerGroup Inc. (MAN) | 100 | 44.0 | -56.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VOLT vs KELYA vs TBI vs CCRN vs MAN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VOLT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 7.7%, EPS growth 103.9%, 3Y rev CAGR -5.2%
- 11.6% 10Y total return vs CCRN's -10.5%
- 7.7% revenue growth vs CCRN's -21.6%
- -0.1% margin vs CCRN's -13.0%
KELYA ranks third and is worth considering specifically for income & stability.
- Dividend streak 5 yrs, beta 1.01, yield 3.2%
- 3.2% yield, 5-year raise streak, vs MAN's 4.7%, (3 stocks pay no dividend)
Among these 5 stocks, TBI doesn't own a clear edge in any measured category.
CCRN is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
- Beta 0.78 vs TBI's 1.13, lower leverage
MAN is the #2 pick in this set and the best alternative if value and efficiency is your priority.
- Lower P/E (8.3x vs 133.8x)
- -0.1% ROA vs CCRN's -19.8%, ROIC 5.6% vs -0.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.7% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (8.3x vs 133.8x) | |
| Quality / Margins | -0.1% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.78 vs TBI's 1.13, lower leverage | |
| Dividends | 3.2% yield, 5-year raise streak, vs MAN's 4.7%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +78.4% vs MAN's -17.0% | |
| Efficiency (ROA) | -0.1% ROA vs CCRN's -19.8%, ROIC 5.6% vs -0.9% |
VOLT vs KELYA vs TBI vs CCRN vs MAN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VOLT vs KELYA vs TBI vs CCRN vs MAN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MAN leads in 2 of 6 categories
VOLT leads 1 • KELYA leads 0 • TBI leads 0 • CCRN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — VOLT and MAN each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MAN is the larger business by revenue, generating $18.0B annually — 23.6x CCRN's $761M. VOLT is the more profitable business, keeping -0.1% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, MAN holds the edge at +7.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $895M | $3.1B | $1.2B | $761M | $18.0B |
| EBITDAEarnings before interest/tax | $6M | -$54M | -$10M | $9M | $236M |
| Net IncomeAfter-tax profit | -$460,000 | -$266M | -$53M | -$99M | -$13M |
| Free Cash FlowCash after capex | $6M | $66M | -$60M | $41M | -$161M |
| Gross MarginGross profit ÷ Revenue | +15.9% | +26.3% | +28.4% | +18.2% | +16.7% |
| Operating MarginEBIT ÷ Revenue | +0.2% | -2.8% | -2.6% | -0.9% | +0.8% |
| Net MarginNet income ÷ Revenue | -0.1% | -8.6% | -4.3% | -13.0% | -0.1% |
| FCF MarginFCF ÷ Revenue | +0.7% | +2.1% | -4.8% | +5.4% | -0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.1% | -100.0% | -100.0% | -100.0% | +7.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | -2.1% | -37.5% | -6.0% | +36.2% |
Valuation Metrics
MAN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, MAN's 9.0x EV/EBITDA is more attractive than TBI's 160.0x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $891M | $349M | $182M | $423M | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $919M | $475M | $329M | $317M | $2.9B |
| Trailing P/EPrice ÷ TTM EPS | 663.16x | -1.34x | -3.73x | -4.47x | -104.90x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.96x | — | 133.84x | 8.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 75.71x | — | 160.03x | 23.75x | 9.02x |
| Price / SalesMarket cap ÷ Revenue | 1.01x | 0.08x | 0.11x | 0.40x | 0.08x |
| Price / BookPrice ÷ Book value/share | 29.32x | 0.35x | 0.65x | 1.31x | 0.69x |
| Price / FCFMarket cap ÷ FCF | 42.93x | 3.06x | — | 10.55x | — |
Profitability & Efficiency
MAN leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MAN delivers a -0.6% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to VOLT's 3.20x. On the Piotroski fundamental quality scale (0–9), VOLT scores 7/9 vs MAN's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -1.5% | -24.6% | -18.7% | -27.1% | -0.6% |
| ROA (TTM)Return on assets | -0.2% | -11.3% | -8.1% | -19.8% | -0.1% |
| ROICReturn on invested capital | +4.5% | -4.0% | -5.2% | -0.9% | +5.6% |
| ROCEReturn on capital employed | +3.0% | -4.3% | -5.3% | -0.8% | +6.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 4 | 6 | 1 |
| Debt / EquityFinancial leverage | 3.20x | 0.16x | 0.62x | 0.01x | 1.16x |
| Net DebtTotal debt minus cash | $28M | $126M | $146M | -$106M | $1.5B |
| Cash & Equiv.Liquid assets | $71M | $33M | $25M | $109M | $871M |
| Total DebtShort + long-term debt | $100M | $159M | $171M | $2M | $2.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.37x | -12.07x | -46.19x | -1.39x | 1.98x |
Total Returns (Dividends Reinvested)
VOLT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VOLT five years ago would be worth $103,993 today (with dividends reinvested), compared to $2,130 for TBI. Over the past 12 months, VOLT leads with a +78.4% total return vs MAN's -17.0%. The 3-year compound annual growth rate (CAGR) favors VOLT at 17.4% vs TBI's -26.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +35.6% | +13.1% | +36.6% | +62.4% | +1.2% |
| 1-Year ReturnPast 12 months | +78.4% | -12.2% | +51.0% | -5.4% | -17.0% |
| 3-Year ReturnCumulative with dividends | +61.8% | -34.2% | -60.2% | -44.3% | -46.4% |
| 5-Year ReturnCumulative with dividends | +939.9% | -58.3% | -78.7% | -22.5% | -64.9% |
| 10-Year ReturnCumulative with dividends | +1164.2% | -33.0% | -68.4% | -10.5% | -30.8% |
| CAGR (3Y)Annualised 3-year return | +17.4% | -13.0% | -26.4% | -17.7% | -18.8% |
Risk & Volatility
Evenly matched — VOLT and CCRN each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than TBI's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VOLT currently trades 96.6% from its 52-week high vs MAN's 64.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 1.01x | 1.13x | 0.78x | 1.03x |
| 52-Week HighHighest price in past year | $41.72 | $14.94 | $7.78 | $14.99 | $47.34 |
| 52-Week LowLowest price in past year | $22.54 | $7.98 | $3.18 | $7.43 | $25.15 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +64.9% | +77.2% | +87.3% | +64.3% |
| RSI (14)Momentum oscillator 0–100 | 76.5 | 63.7 | 83.2 | 53.1 | 47.1 |
| Avg Volume (50D)Average daily shares traded | 290K | 361K | 386K | 552K | 1.1M |
Analyst Outlook
Evenly matched — KELYA and MAN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: KELYA as "Buy", TBI as "Buy", CCRN as "Hold", MAN as "Hold". Consensus price targets imply 54.6% upside for KELYA (target: $15) vs -18.9% for CCRN (target: $11). For income investors, MAN offers the higher dividend yield at 4.71% vs KELYA's 3.23%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | — | $15.00 | $5.75 | $10.61 | $37.86 |
| # AnalystsCovering analysts | — | 5 | 10 | 14 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | +3.2% | — | — | +4.7% |
| Dividend StreakConsecutive years of raises | — | 5 | 0 | 1 | 0 |
| Dividend / ShareAnnual DPS | — | $0.31 | — | — | $1.43 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.5% | +0.6% | +1.6% | +2.7% |
MAN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). VOLT leads in 1 (Total Returns). 3 tied.
VOLT vs KELYA vs TBI vs CCRN vs MAN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VOLT or KELYA or TBI or CCRN or MAN a better buy right now?
For growth investors, Volt Information Sciences, Inc.
(VOLT) is the stronger pick with 7. 7% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Volt Information Sciences, Inc. (VOLT) offers the better valuation at 663. 2x trailing P/E, making it the more compelling value choice. Analysts rate Kelly Services, Inc. (KELYA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VOLT or KELYA or TBI or CCRN or MAN?
On forward P/E, ManpowerGroup Inc.
is actually cheaper at 8. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VOLT or KELYA or TBI or CCRN or MAN?
Over the past 5 years, Volt Information Sciences, Inc.
(VOLT) delivered a total return of +939. 9%, compared to -78. 7% for TrueBlue, Inc. (TBI). Over 10 years, the gap is even starker: VOLT returned +1164% versus TBI's -68. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VOLT or KELYA or TBI or CCRN or MAN?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus TrueBlue, Inc. 's 1. 13β — meaning TBI is approximately 46% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 3% for Volt Information Sciences, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VOLT or KELYA or TBI or CCRN or MAN?
By revenue growth (latest reported year), Volt Information Sciences, Inc.
(VOLT) is pulling ahead at 7. 7% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Volt Information Sciences, Inc. grew EPS 103. 9% year-over-year, compared to -427. 4% for Kelly Services, Inc.. Over a 3-year CAGR, MAN leads at -3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VOLT or KELYA or TBI or CCRN or MAN?
Volt Information Sciences, Inc.
(VOLT) is the more profitable company, earning 0. 2% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 0. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MAN leads at 1. 3% versus -1. 7% for TBI. At the gross margin level — before operating expenses — TBI leads at 21. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VOLT or KELYA or TBI or CCRN or MAN more undervalued right now?
On forward earnings alone, ManpowerGroup Inc.
(MAN) trades at 8. 3x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 125. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KELYA: 54. 6% to $15. 00.
08Which pays a better dividend — VOLT or KELYA or TBI or CCRN or MAN?
In this comparison, MAN (4.
7% yield), KELYA (3. 2% yield) pay a dividend. VOLT, TBI, CCRN do not pay a meaningful dividend and should not be held primarily for income.
09Is VOLT or KELYA or TBI or CCRN or MAN better for a retirement portfolio?
For long-horizon retirement investors, Volt Information Sciences, Inc.
(VOLT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1164% 10Y return). Both have compounded well over 10 years (VOLT: +1164%, TBI: -68. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VOLT and KELYA and TBI and CCRN and MAN?
These companies operate in different sectors (VOLT (Industrials) and KELYA (Industrials) and TBI (Industrials) and CCRN (Healthcare) and MAN (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: VOLT is a small-cap quality compounder stock; KELYA is a small-cap income-oriented stock; TBI is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; MAN is a small-cap income-oriented stock. KELYA, MAN pay a dividend while VOLT, TBI, CCRN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.